Dow Jones Today: Stock Futures Rise After Losing Week; Gold Hits Record, Dollar Slips Ahead of Possible Government Shutdown

Stock futures gained early Monday after major indexes posted a losing week, but the dollar fell on fears of a possible government shutdown this week.

Futures associated with the tech-heavy Nasdaq, benchmark S&P 500, and blue-chip Dow Jones Industrial Average were up 0.6%, 0.5%, and 0.4%, respectively. The indexes closed higher Friday to snap a three-session losing streak after a key inflation report matched expectations, but nevertheless finished lower for the week.

The U.S. dollar index, which tracks the value of the greenback against a basket of foreign currencies, was down 0.2% to 97.97 and safe-haven gold advanced 1% to a record-high $3,845 ahead of a looming deadline for lawmakers to strike a deal to avoid a federal government shutdown. President Donald Trump was set to meet with congressional leaders Monday ahead of the deadline, set for 12:01 a.m. ET Wednesday.

The 10-year Treasury yield, which affects borrowing costs on a variety of consumer and commercial loans, fell to 4.14% from roughly 4.19% Friday afternoon. West Texas Intermediate futures, the U.S. crude oil benchmark, fell 2% to $64.50 per barrel following a report that OPEC and its allies plan another output hike in November. Bitcoin rose 1.6% to above $112,000.

U.S.-listed shares of GSK (GSK) surged nearly 4% in premarket trading as the British pharmaceutical company said CEO Emma Walmsley will be stepping down, with Chief Commercial Officer Luke Miels set to replace her Jan. 1. Those of fellow British firm AstraZeneca (AZN) advanced more than 1% as it plans to directly list on the New York Stock Exchange.

U.S.-listed shares of Danish drugmaker Novo Nordisk (NVO) fell 3% before the bell as Morgan Stanley cut its rating on the stock to “underweight” and slashed its price target, saying a trial to see whether semaglutide— the main ingredient in blockbuster weight-loss drugs Wegovy and Ozempic—also will work against Alzheimer’s disease is likely to fail.